KARACHI: ICI Pakistan Limited announced that on Monday the company executed Asset Purchase Agreements with Wyeth Pakistan Limited and Pfizer Pakistan Limited, for the acquisition of certain assets at the aggregate purchase price of Rs1.91 billion.
A statement said the assets being acquired by ICI Pakistan Limited through this transaction included a Wyeth Pakistan Limited-owned pharmaceutical manufacturing facility located on Hawkes Bay Road, SITE, in Karachi. The acquisition includes products and registrations including the following popular and well-established pharmaceutical brands: Entox-P, Lederplex, Lederrif, Mucaine, Nilstat, TriHEMIC and Wymox.
In addition, two products and registrations of Pfizer Pakistan Limited are also included in the acquisition, namely: Citralka and Combantrin, the statement added. It said the transaction is now set to move ahead, subject to requisite regulatory approvals.
Chinese power company had intended to acquire up to 18.336 billion ordinary shares of K-Electric, representing 66.4...
MARI also successfully drilled and tested another appraisal well in the Mari Ghazij formation located in Mari D&PL
Gold rates decreased by $30 to $2,381 per ounce in the international market
Growing number of Americans have seen their savings dwindle as rising prices squeeze budgets while interest rates stay...
IMF will closely watch the privatization of PIA by the end of June
PSX lays down the groundwork to encourage listed companies to adopt ESG reporting in line with global standards
